Literature DB >> 7697714

Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome).

R J Gibbons1, D J Picketts, L Villard, D R Higgs.   

Abstract

The ATR-X syndrome is an X-linked disorder comprising severe psychomotor retardation, characteristic facial features, genital abnormalities, and alpha-thalassemia. We have shown that ATR-X results from diverse mutations of XH2, a member of a subgroup of the helicase superfamily that includes proteins involved in a wide range of cellular functions, including DNA recombination and repair (RAD16, RAD54, and ERCC6) and regulation of transcription (SW12/SNF2, MOT1, and brahma). The complex ATR-X phenotype suggests that XH2, when mutated, down-regulates expression of several genes, including the alpha-globin genes, indicating that it could be a global transcriptional regulator. In addition to its role in the ATR-X syndrome, XH2 may be a good candidate for other forms of X-linked mental retardation mapping to Xq13.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7697714     DOI: 10.1016/0092-8674(95)90287-2

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  177 in total

Review 1.  Chromatin modification and disease.

Authors:  C A Johnson
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

Review 2.  Genetic effects on human cognition: lessons from the study of mental retardation syndromes.

Authors:  P Nokelainen; J Flint
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-03       Impact factor: 10.154

3.  ASAP, a novel protein complex involved in RNA processing and apoptosis.

Authors:  Christian Schwerk; Jayendra Prasad; Kurt Degenhardt; Hediye Erdjument-Bromage; Eileen White; Paul Tempst; Vincent J Kidd; James L Manley; Jill M Lahti; Danny Reinberg
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

4.  The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies.

Authors:  Yutong Xue; Richard Gibbons; Zhijiang Yan; Dafeng Yang; Tarra L McDowell; Salvatore Sechi; Jun Qin; Sharleen Zhou; Doug Higgs; Weidong Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-02       Impact factor: 11.205

5.  Dnmt3L is a transcriptional repressor that recruits histone deacetylase.

Authors:  Rachel Deplus; Carmen Brenner; Wendy A Burgers; Pascale Putmans; Tony Kouzarides; Yvan de Launoit; François Fuks
Journal:  Nucleic Acids Res       Date:  2002-09-01       Impact factor: 16.971

6.  2003 William Allan Award address. The Thalassemias: the role of molecular genetics in an evolving global health problem.

Authors:  David Weatherall
Journal:  Am J Hum Genet       Date:  2004-03       Impact factor: 11.025

7.  Epigenetics and assisted reproductive technology: a call for investigation.

Authors:  Emily L Niemitz; Andrew P Feinberg
Journal:  Am J Hum Genet       Date:  2004-02-27       Impact factor: 11.025

8.  Missense variants in the chromatin remodeler CHD1 are associated with neurodevelopmental disability.

Authors:  Genay O Pilarowski; Hilary J Vernon; Carolyn D Applegate; Leandros Boukas; Megan T Cho; Christina A Gurnett; Paul J Benke; Erin Beaver; Jennifer M Heeley; Livija Medne; Ian D Krantz; Meron Azage; Dmitriy Niyazov; Lindsay B Henderson; Ingrid M Wentzensen; Berivan Baskin; Maria J Guillen Sacoto; Gregory D Bowman; Hans T Bjornsson
Journal:  J Med Genet       Date:  2017-09-02       Impact factor: 6.318

Review 9.  Alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas.

Authors:  Xiaolei Ren; Chao Tu; Zhenchu Tang; Ruofei Ma; Zhihong Li
Journal:  Oncol Lett       Date:  2018-03-22       Impact factor: 2.967

10.  Alpha thalassemia/mental retardation syndrome X-linked gene product ATRX is required for proper replication restart and cellular resistance to replication stress.

Authors:  Justin Wai-Chung Leung; Gargi Ghosal; Wenqi Wang; Xi Shen; Jiadong Wang; Lei Li; Junjie Chen
Journal:  J Biol Chem       Date:  2013-01-16       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.